

---

---

**Cardiovascular implants and artificial  
organs — Hard-shell cardiotomy/  
venous reservoir systems (with/  
without filter) and soft venous  
reservoir bags**

*Implants cardiovasculaires et organes artificiels — Systèmes  
réservoirs de cardiotomie/veineux à paroi dure (avec/sans filtre) et  
sacs réservoirs veineux mous*



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2016, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Ch. de Blandonnet 8 • CP 401  
CH-1214 Vernier, Geneva, Switzerland  
Tel. +41 22 749 01 11  
Fax +41 22 749 09 47  
copyright@iso.org  
www.iso.org

# Contents

Page

Foreword .....	iv
<b>1 Scope .....</b>	<b>1</b>
<b>2 Normative references .....</b>	<b>1</b>
<b>3 Terms and definitions .....</b>	<b>1</b>
<b>4 Requirements .....</b>	<b>3</b>
4.1 Biological characteristics .....	3
4.1.1 Sterility and non-pyrogenicity .....	3
4.1.2 Biocompatibility .....	3
4.2 Physical characteristics .....	3
4.2.1 General .....	3
4.2.2 Blood volumes .....	4
4.2.3 Connectors .....	4
4.3 Performance characteristics .....	4
4.3.1 Blood cell damage .....	4
4.3.2 Air-handling capacity .....	4
4.3.3 Priming volume of the reservoirs in accordance with the manufacturer's quality control management system .....	4
4.3.4 Defoaming characteristics .....	4
4.3.5 Volume calibration .....	4
4.3.6 Filtration efficiency .....	5
4.3.7 Break-through volume .....	5
4.3.8 Dynamic priming volume .....	5
4.3.9 Minimum and maximum volumes .....	5
4.3.10 Shelf life .....	5
<b>5 Tests and measurements to determine compliance with this document .....</b>	<b>5</b>
5.1 General .....	5
5.2 Biological characteristics .....	5
5.2.1 Sterility and non-pyrogenicity .....	5
5.2.2 Biocompatibility .....	6
5.3 Physical characteristics .....	6
5.3.1 Blood pathway integrity for soft venous reservoir bags .....	6
5.3.2 Blood pathway integrity for sealed hard-shell reservoirs .....	6
5.3.3 Connectors .....	6
5.3.4 Blood cell damage .....	6
5.3.5 Filtration efficiency .....	7
5.3.6 Shelf life .....	7
<b>6 Information supplied by the manufacturer .....</b>	<b>7</b>
6.1 Information on the reservoir (labelling) .....	7
6.2 Information on the packaging .....	8
6.2.1 Information on the unit container .....	8
6.2.2 Information on the shipping container .....	8
6.3 Information in the accompanying documents .....	8
6.4 Information in the accompanying documents in a prominent form .....	9
<b>7 Packaging .....</b>	<b>9</b>
<b>Annex A (normative) Factors to be considered in evaluating performance characteristics .....</b>	<b>10</b>
<b>Bibliography .....</b>	<b>11</b>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

The committee responsible for this document is ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

This third edition cancels and replaces the second edition (ISO 15674:2009), which has been technically revised.

# Cardiovascular implants and artificial organs — Hard-shell cardiotomy/venous reservoir systems (with/without filter) and soft venous reservoir bags

## 1 Scope

This document specifies requirements for sterile, single-use, extracorporeal hard-shell cardiotomy/venous reservoir systems and soft venous reservoir bags intended for use as a blood reservoir during cardiopulmonary bypass (CPB) surgery.

This document applies only to the blood reservoir aspects for multifunctional systems which can have integral parts such as blood-gas exchangers (oxygenators), blood filters, defoamers, blood pumps, etc.

## 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-7, *Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals*

ISO 10993-11, *Biological evaluation of medical devices — Part 11: Tests for systemic toxicity*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 11607-2, *Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes*

ISO 14937, *Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices*

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

## 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

- 3.1**  
**hard-shell cardiomy reservoir**  
extracorporeal device consisting of rigid walls designed to collect, defoam and filter suctioned blood
- 3.2**  
**hard-shell venous reservoir**  
extracorporeal device consisting of rigid walls designed to collect and defoam venous blood
- 3.3**  
**soft-bag venous reservoir**  
extracorporeal device consisting of collapsible, pliable walls designed to collect venous blood
- 3.4**  
**hard-shell cardiomy/venous reservoir system**  
extracorporeal device designed to function simultaneously as both a venous reservoir and cardiomy reservoir
- 3.5**  
**blood-gas exchanger**  
**oxygenator**  
extracorporeal device designed to supplement, or be a substitute for, the respiratory function of the lungs
- 3.6**  
**integral part**  
part that is connected to the reservoir or is part of the reservoir system that cannot normally be separated by the user
- 3.7**  
**operating variable**  
setting of controls which affects the function of the device
- 3.8**  
**static volume**  
priming volume present in the device at zero flow
- 3.9**  
**break-through volume**  
volume of fluid that, when added during the initial priming of the dry device (as received from the manufacturer), must be exceeded before fluid first exits the device
- 3.10**  
**sealed hard-shell reservoir**  
hard-shell reservoir that may be operated at either positive or negative pressure
- 3.12**  
**dynamic priming volume**  
amount of fluid volume that is contained inside the defoamer/filter compartment at a specified flow rate and, for soft bag reservoir, depending on the head pressure and the position of the compression mechanism
- Note 1 to entry: The dynamic priming volume can be affected by negative pressure applied to a hard-shell reservoir.
- 3.13**  
**platelet reduction**  
percentage reduction of platelets contained in a circuit as a function of time
- 3.14**  
**plasma-free haemoglobin level**  
concentration of plasma-free haemoglobin in a circuit as a function of time

### 3.14.1 normalized index of hemolysis NIH

grams of plasma-free hemoglobin released after pumping 100 L of blood

$$NIH \left( \text{g} / 100 \text{L} \right) = \Delta fHb \times V \times \frac{100 - Hct}{100} \times \frac{100}{Q \times T}$$

where

$\Delta fHb$  increase of plasma free hemoglobin concentration (g/L) over the sampling time interval;

$V$  circuit volume (L);

$Q$  flow rate (L/min);

$Hct$  hematocrit (%);

$T$  sampling time interval (min)

### 3.15 white blood cell reduction

percentage reduction of white blood cells contained in a circuit as a function of time

### 3.16 predicate reservoir

similar reservoir to the test reservoir that has previously been approved and used for the same intended clinical use

### 3.17 filtration efficiency

ability of the filter to remove particles from the simulated blood suspension test fluid, expressed as a percentage

## 4 Requirements

### 4.1 Biological characteristics

#### 4.1.1 Sterility and non-pyrogenicity

The blood pathway shall be sterile and non-pyrogenic.

Compliance shall be verified in accordance with [5.2.1](#).

#### 4.1.2 Biocompatibility

All parts of the blood pathway shall be biocompatible with respect to their intended use.

Compliance shall be verified in accordance with [5.2.2](#).

### 4.2 Physical characteristics

#### 4.2.1 General

When tested in accordance with [5.3.1](#) and [5.3.2](#), the blood pathway shall not leak.

### 4.2.2 Blood volumes

The volume of the blood pathway shall be within the tolerances specified by the manufacturer [see [6.3 k](#)].

### 4.2.3 Connectors

Connectors for connection to the blood pathway shall, when tested in accordance with [5.3.4](#), allow a secure connection.

NOTE 1 Connectors of a type that allows connection of tubes with an inner diameter of 4,8 mm, 6,3 mm, 9,5 mm, or 12,7 mm, or a type that complies with ISO 8637:2010, Figure 1 or a type that complies with ISO 594-2, have been used.

NOTE 2 Connectors corresponding to ISO 8637:2010, Figure 3 are considered as one way to comply with this requirement.

## 4.3 Performance characteristics

NOTE 1 Guidance for testing is given in [Annex A](#).

NOTE 2 Some of these tests can be combined and performed at the same time.

### 4.3.1 Blood cell damage

#### 4.3.1.1 Plasma-free haemoglobin

When determined in accordance with [5.3.4](#), the increased concentration of plasma-free haemoglobin shall be within the range of values specified by the manufacturer.

The hemolysis results shall be reported as mg/dL and NIH.

#### 4.3.1.2 Platelet reduction and white blood cell reduction

When determined in accordance with [5.3.4](#), the percentage reduction of platelets and the percentage reduction of white blood cells shall be within the range of values specified by the manufacturer.

### 4.3.2 Air-handling capacity

Testing to demonstrate the air-handling characteristics shall be conducted at various flow rates and the results shall be recorded [see [6.3 p](#)]. The test shall be conducted according to the manufacturer's protocols.

### 4.3.3 Priming volume of the reservoirs in accordance with the manufacturer's quality control management system

The volume of the reservoir(s) shall be determined and the results presented in accordance with [6.3 o](#)). Testing shall be conducted according to the manufacturer's protocols.

### 4.3.4 Defoaming characteristics

Where applicable, the defoaming characteristics shall be determined and the results shall be recorded [see [6.3 p](#)]. The testing shall be conducted according to the manufacturer's protocols.

### 4.3.5 Volume calibration

Where applicable, the accuracy of the volume markings shall be measured and tolerances shall be presented as required in [6.3 n](#)). The testing shall be conducted according to the manufacturer's protocols.



#### 4.3.6 Filtration efficiency

The efficiency of the filter shall be determined by the manufacturer according to their protocol. The filter efficiency results shall be recorded [see 6.3 p)]. The testing shall be performed around the anticipated flow range of the filter.

#### 4.3.7 Break-through volume

Where applicable, the break-through volume shall be measured and the results shall be recorded [see 6.3 p)]. The testing shall be performed according to the manufacturer's protocols.

#### 4.3.8 Dynamic priming volume

Where applicable, the dynamic priming volume applies to hard-shell cardiotomy/venous reservoir systems (with/without filter) and shall be measured and reported as in 6.3 k). Results shall indicate the priming volume over the entire range of flows specified by the manufacturer and operational volume used for the test. Testing shall be performed according to the manufacturer's protocols.

#### 4.3.9 Minimum and maximum volumes

The minimum and maximum volumes shall be specified by the manufacturers in the testing protocols.

#### 4.3.10 Shelf life

When tested in accordance with 5.3.4, test results shall demonstrate the rated shelf life, as specified by the manufacturer.

## 5 Tests and measurements to determine compliance with this document

### 5.1 General

5.1.1 Tests and measurements shall be performed with the device under test prepared according to the manufacturer's instructions for intended clinical use.

5.1.2 Operating variables shall be those specified by the manufacturer for intended clinical use, unless otherwise specified.

5.1.3 Unless otherwise stated, the temperature of test liquids shall be  $(37 \pm 1) ^\circ\text{C}$ .

5.1.4 If the relationship between variables is nonlinear, sufficient determinations shall be made to permit valid interpolation between data points.

5.1.5 The test or measurement procedures are to be regarded as reference procedures. Other procedures can be accepted provided that the alternative procedure has been shown to be of comparable precision.

### 5.2 Biological characteristics

#### 5.2.1 Sterility and non-pyrogenicity

Compliance shall be verified by inspection of the manufacturer's documentation on sterilization and pyrogen testing, in accordance with ISO 17665-1, ISO 11135, ISO 11137-1, ISO 14937, or ISO 10993-11, as applicable.

## 5.2.2 Biocompatibility

Compliance shall be verified by inspection of the manufacturer's documentation on biocompatibility for the finished device in accordance with ISO 10993-1 and ISO 10993-7.

## 5.3 Physical characteristics

### 5.3.1 Blood pathway integrity for soft venous reservoir bags

Subject the blood pathway of the device, filled with water, to a positive pressure of  $1,5 \times$  the manufacturer's rated pressure or, if none is given, to a pressure of 152 kPa (22 psi) gauge and maintain this pressure for 6 h or for the intended time of use specified by the manufacturer. Visually inspect the device for evidence of water leakage.

### 5.3.2 Blood pathway integrity for sealed hard-shell reservoirs

5.3.2.1 Perform the test with air or water at the appropriate pressures.

5.3.2.2 Subject the blood pathway of the device to a negative or positive pressure of  $1,5 \times$  the manufacturer's rated pressure and maintain this pressure for 6 h or for the intended time of use specified by the manufacturer. Using air pressure decay or visual inspection, check for evidence of leakage.

NOTE If the hard-shell reservoirs are only operated at atmospheric pressure, the test for blood pathway integrity needs to be performed at atmospheric pressure on these units.

### 5.3.3 Connectors

The connection shall be made in accordance with the manufacturer's instructions for use. The connection shall withstand a pull force of 15 N for 15 s without separating.

### 5.3.4 Blood cell damage

#### 5.3.4.1 Test media

The test liquid for the blood pathway shall be anticoagulated whole blood.

#### 5.3.4.2 Procedure

Two sets of appropriate, identical circuit components, including a pump, connecting tubing, a reservoir (as specified by the manufacturer and of suitable size relative to the device under test) and a heat exchanger, shall be assembled. The device under test shall be placed in one of the circuits. A predicate device shall be placed in the second test circuit. Priming and debubbling of the circuits by recirculating with an appropriate solution is recommended before blood is added. The blood pathway test-liquid volumes shall, at the initiation of the test, be within 1 % of each other. Perform the test *in vitro* using the conditions given in [Table 1](#). A sufficient number of paired tests should be performed to support a statistical analysis. The predicate reservoir should be tested under the same conditions.

**Table 1 — Conditions for *in vitro* testing of blood cell damage**

Item	Level	Maximum variation
Blood flow rate	The maximum specified by the manufacturer for intended clinical use (see <a href="#">6.3</a> )	$\pm 5 \%$
Blood glucose	10 mmol/l	$\pm 5$ mmol/l
Haemoglobin	12 g/dl	$\pm 1$ g/dl

The sampling schedule shall be in accordance with [Table 2](#). More frequent sampling times are optional.

**Table 2 — Sampling schedule**

Parameter	Time, after initiation of test (min)			
	Prior to test	30	180	360
Plasma-free haemoglobin	X	X	X	X
White blood cell	X	X	X	X
Platelets	X	X	X	X
Haemoglobin	X	X	X	X
Glucose	X			
Activated clotting time	X	X	X	X
Temperature	X	X	X	X
Flow rates	X	X	X	X

### 5.3.5 Filtration efficiency

#### 5.3.5.1 Test liquid

The test liquid shall be a glycerin solution or water. The test liquid shall contain 350 particles per ml to 5 000 particles per ml that are 15 % to 25 % larger than the nominal pore size of the reservoir filter.

#### 5.3.5.2 Procedure

Pass 500 ml of the test liquid at room temperature (20 °C to 22 °C) through the reservoir filter at a flow rate of no less than 100 ml/min and a pressure not exceeding 152 kPa (22 psi) gauge. Determine the pre- and post-filtration mean number of particles. The test shall be performed at the manufacturer's recommended flow rates. Calculate the filtration efficiency, using the readings from the size range of the test particles used for each test sample, by subtracting the post-filtration mean number of particles from the pre-filtration mean, dividing the quotient by the pre-filtration mean number of particles, and multiplying by 100 to obtain a percentage.

### 5.3.6 Shelf life

Using a validated method, ageing should be performed on final, finished, sterilized, devices in primary packaging in order to determine nominal shelf life.

## 6 Information supplied by the manufacturer

### 6.1 Information on the reservoir (labelling)

The following shall be provided on the reservoir:

- a) the manufacturer's identity;
- b) batch, lot or serial number designation;
- c) model designation;
- d) the direction of blood flow, if necessary.

## **6.2 Information on the packaging**

### **6.2.1 Information on the unit container**

The following shall be given on the unit container:

- a) the manufacturer's name and address;
- b) description of contents;
- c) model designation;
- d) statement on sterility and non-pyrogenicity;
- e) batch, lot or serial number designation;
- f) the statement "Read instructions before use" or equivalent symbol;
- g) special handling or storage conditions;
- h) statement on single-use;
- i) expiry date.

### **6.2.2 Information on the shipping container**

The following shall be provided on the shipping container:

- a) the manufacturer's name and address;
- b) description of contents, including number of units;
- c) model designation;
- d) statement on sterility and non-pyrogenicity;
- e) special handling, storage or unpacking instructions;
- f) lot number or serial number.

## **6.3 Information in the accompanying documents**

Each shipping container shall contain an "Instructions for Use" leaflet with the following information:

- a) the manufacturer's address and telephone and fax number;
- b) model designation;
- c) required ancillary equipment;
- d) instructions on necessary, special or unique procedures applicable;
- e) placement, type and securing of tubing connections;
- f) location and purpose of additional entry or exit ports;
- g) direction of blood flow;
- h) general operating procedures for normal use;
- i) a recommended procedure for intraoperative replacement of a reservoir system;
- j) maximum and minimum recommended blood flow rates;

- k) maximum and minimum operating volumes of the blood pathway, including any integral reservoir and dynamic priming volume;
- l) pressure limitations for blood pathways;
- m) the static volume and summary of the protocol used;
- n) tolerance of scales used for blood measurements;
- o) the priming volume of the filter (if applicable);
- p) a statement that the following are available upon request:
  - 1) sterilization method;
  - 2) a list of the materials comprising the blood pathway;
  - 3) data related to blood cell damage and a summary of the protocol used;
  - 4) relevant tolerances for data presented;
  - 5) air-handling capability and summary of the protocol used;
  - 6) antifoam characteristics and a summary of the protocol used;
  - 7) break-through volume;
  - 8) filtration efficiency.

#### **6.4 Information in the accompanying documents in a prominent form**

The following information shall be provided in a prominent form in the accompanying documents:

- a) pressure limitations;
- b) flow rate limitations;
- c) blood level limitation;
- d) other device limitations, e.g. material incompatibility with known volatile anaesthetic agents, solvents or disinfectants.

### **7 Packaging**

Packaging shall comply with the appropriate requirements of ISO 11607-1 and ISO 11607-2.

## Annex A (normative)

### Factors to be considered in evaluating performance characteristics

To help clarify [4.3.1](#) to [4.3.8](#), the following should be considered where a) refers to [4.3.1](#), b) refers to [4.3.2](#), etc.

- a) The cell-damage data reported in [6.3](#) p) shall include, but not be limited to, the following: plasma haemoglobin, generated plasma haemoglobin, index of haemolysis, white cell count, and platelet count.
- b) The air-handling characteristics shall be determined for both large boluses of air and for small air bubbles over time. The characteristics shall be determined over at least 6 h or for the time specified in the labelling as the maximum usable time of the reservoir. Measurements of air-handling capacity shall be dynamic.
- c) The priming volume of the reservoir is the minimum volume specified by the manufacturer.
- d) The ability of the reservoir to defoam the blood shall be measured. Defoaming may be tested as part of the air-handling characteristics.
- e) The accuracy of the volume measurement markings shall be tested and the tolerance calculated over the entire range and the results published in the labelling.
- f) The filter efficiency shall be measured using a technique that is sufficient to determine the size of the particles that will be held up in the reservoir.
- g) The break-through volume of the reservoir is defined in [3.9](#).
- h) The dynamic priming volume is based on the volume in the reservoir as the flow increases over the entire range of operations.

## Bibliography

- [1] ISO 594-2, *Conical fittings with 6 % (Luer) taper for syringes, needles and certain other medical equipment — Part 2: Lock fittings*
- [2] ISO 7199, *Cardiovascular implants and artificial organs — Blood-gas exchangers (oxygenators)*
- [3] ISO 8637, *Cardiovascular implants and extracorporeal systems — Haemodialysers, haemodiafilters, haemofilters and haemoconcentrators*
- [4] ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*
- [5] ISO 14971, *Medical devices — Application of risk management to medical devices*
- [6] ISO/TS 23810, *Cardiovascular implants and artificial organs — Checklist for preoperative extracorporeal circulation equipment setup*

